PRNewsWire Link Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing...
Read More
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
Read More
Pulmatrix and Eos merge to advance gerotherapeutics
Read More
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan PRN Newswire Release • Combined...
Read More
Ponce Aurora is developing consumer products powered by its proprietary MitoXcel™ Technology, the first information- and AI-driven mitochondrial-targeted geropeptides addressing a fundamental cause of aging. Appointment...
Read More
DynaFlex™ Incorporates MetaDirectional Flex™ Technology to Create the First-of-Its-Kind Programmable Mesh Our introduction of DynaFlex™ represents a new era in...
Read More
• Launches Hernia Division to Focus on Abdominal Wall Repair Solutions • Strengthens Leadership to Drive Market Readiness for Surgical...
Read More
Agreement focuses on rimiducid, an agent used to activate certain “safety switch” cell elimination technologies in cell and gene therapies...
Read More
Saunders was previously CEO of Allergan, the company that developed and launched Botox™ until the company’s $63 billion acquisition by...
Read More
